ArticleFrontiers in public health2026
A cross-sectional study of seroprevalence in Armenia, 2025: measles, mumps, rubella, and diphtheria.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prevention and control of vaccine-preventable infections is a key component of maintaining public health, and the overall state of immunity is the determining factor. Objective of the study: To study herd immunity of the Armenian population to measles, rubella, mumps, and diphtheria. Materials and methods: The study involved 5,513 individuals from all regions aged from 1 year and above. A cohort of volunteers, stratified into 9 age groups, was formed including by region and activity using a web application. For each infection, the presence and/or levels of immunoglobulin G were determined by the enzyme immunoassay method using Russian-made test systems. Results: The cohort average seroprevalence values for measles, rubella, mumps, and diphtheria were 88.3%, 97.2, 83.2, and 56.3%, respectively. The least protected age groups were: children <5 years (80.7% seropositive) and adults 30-49 years (82-83%) regarding measles; adolescents and adults <49 years (73-79%) regarding mumps; and the older adults (34.4%) regarding diphtheria. Most volunteers had: low or moderate measles Ab levels (0.18-1 IU/mL); high levels of rubella Abs (>200 IU/mL); and a basic protective level of diphtheria toxin Abs (0.1-1 IU/mL). With age, a trend is seen: seropositivity for the viral pathogens (measles, mumps, and rubella) increased to maximum values; and diphtheria seropositivity decreased to minimum values. Conclusion: The level of herd immunity in Armenia is sufficient only for rubella, as confirmed by the absence of cases. Currently, immunity to measles and mumps is present, which prevents outbreaks but may not be fully preventive of sporadic cases. Despite the absence of diphtheria, insufficient protection in older adults makes them a risk group for incidence and severity. However, immunity levels in our study were assessed based only on humoral immunity, which may underrepresent the full immunological response, including that mediated by cellular immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.